DALLAS-- (BUSINESS WIRE) -- Kendall Law Group, founded by a former federal judge, began an investigation on behalf of IMS Health Inc. (NYSE: RX) shareholders. The investigation concerns possible breaches of fiduciary duty by the Board of Directors in connection with the proposed acquisition by private equity firm Texas Pacific Group and the CPP Investment Board of Toronto. The transaction is valued at approximately $4 billion, including the assumption of debt.

According to the agreement, IMS shareholders will receive $22 in cash for each share owned, which is an almost 31% premium based on the closing price of IMS on November 4, 2009. Former federal judge Joe Kendall said, “The investigation concerns whether the consideration to be paid to shareholders is grossly unfair, inadequate, and substantially below the fair or inherent value of IMS and whether the directors and special committee members may have breached their fiduciary duties by not acting in the shareholders’ best interests in connection with the sale process.”

If you are a current holder of IMS stock and would like additional information concerning this proposed transaction, including your shareholder rights, contact Hamilton Lindley at 877-744-3728 or by email at hlindley@kendalllawgroup.com.

Kendall Law Group has substantial experience representing investors in mergers and acquisitions nationwide. Lawyers at the firm include a former United States Attorney, a former Dallas state and federal judge, and experienced securities lawyers.